Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Overview

Explore BioCryst Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

BCRX●NASDAQ
HealthcareBiotechnology
$9.58
$0.24(2.57%)
U.S. Market opens in 15h 20m

BioCryst Pharmaceuticals, Inc. (BCRX)

Meyka AI Score

Z

Key Financials

Market Cap2.4B
P/E Ratio-5.64
EPS (TTM)$1.30
ROE1.24%
Fundamental Analysis

AI Price Forecasts

1 Month$9.01
3 Months$6.88
1 Year Target$9.62

BCRX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, BioCryst Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of BCRX on the NASDAQ shows an RSI of 52.40, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $9.62 for the NASDAQ listing.

Key metrics behind BioCryst Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -5.64 and a market capitalization of 2.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BCRX on the NASDAQ.

Price Performance (NASDAQ: BCRX)

1-Day Change
2.57%
5-Day Change
2.24%
1-Month Change
-3.62%
3-Month Change
7.64%
6-Month Change
41.72%
Year-to-Date (YTD) Change
22.82%
1-Year Change
15.98%
3-Year Change
23.61%
5-Year Change
-42.98%
All-Time (Max) Change
47.38%

Contact Information

https://www.biocryst.com
919 859 1302
4505 Emperor Boulevard, Durham, NC, 27703

Company Facts

4,350 Employees
IPO DateMar 4, 1994
CountryUS
Actively Trading

Frequently Asked Questions